翰思艾泰再次递表港交所 去年亏损约1.17亿元

Core Viewpoint - Hanse Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with ICBC International as the sole sponsor, despite being in a loss-making position for the fiscal years 2023 and 2024 [1][4]. Company Overview - Hanse Aitai is an innovative biotechnology company specializing in structural biology, translational medicine, and clinical development, with a pipeline that includes one core product and nine other candidate products [4][6]. - The core product, HX009, is a self-developed PD-1/SIRPα dual-function antibody fusion protein, which has completed Phase I clinical trials in Australia and China [4][5]. Product Pipeline - The company has three ongoing clinical projects for HX009 in China, targeting advanced melanoma, relapsed/refractory Epstein-Barr virus-positive non-Hodgkin lymphoma, and advanced biliary tract cancer [5]. - Two other major products, HX301 and HX044, are in clinical stages, focusing on cancer treatment. HX301 is a multi-target kinase inhibitor, while HX044 is a novel dual-function anti-CTLA-4 antibody SIRPα fusion protein [5][6]. Financial Performance - For the fiscal years 2023 and 2024, the company reported other income and revenue of approximately RMB 6.664 million and RMB 7.681 million, respectively, while incurring losses of about RMB 85.16 million and RMB 117 million [6][8]. - The company has a total of ten candidate drugs in its pipeline, with eight targeting oncology and two for autoimmune diseases [6].